Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins

被引:25
作者
Quan, Fu-Shi
Sailaja, Gangadhara
Skountzou, Ioanna
Huang, Chunzi
Vzorov, Andrei
Compans, Richard W.
Kang, Sang-Moo
机构
[1] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA
关键词
HIV-1; virus-like particles; modification; immunogenicity;
D O I
10.1016/j.vaccine.2007.01.107
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Extensive glycosylation and variable loops of the HIV envelope protein (Env) are reported to shield some neutralizing epitopes. Here, we investigated the immunogenicity of mutated HIV Envs presented in virus-like particles (VLPs). We immunized mice with simian human immunodeficiency virus (SHIV) VLPs containing mutant HIV Env with reduced glycosylation (3G), variable loop-deleted mutations (dV1V2), or combinations of both types of mutations (3G-dV2-1G), and evaluated immune responses. Immune sera from mice that received VLPs with modified HIV Envs (3G or dV1V2) showed higher neutralizing activities against the homologous HIV 89.6 virus as well as heterologous viruses when compared with wild type SHIV VLP-immunized mice. Lymphocytes from immunized mice produced HIV Env-specific cytokines, with the 3G-dV2-1G mutant producing high levels of cytokines. Interestingly, both dendritic cells and B cells were found to interact with VLPs suggesting that VLPs are effective immunogens. Therefore, this study suggests that VLPs containing modified HIV Env have the potential to be developed as candidate vaccines capable of inducing cellular and humoral immune responses including neutralizing activities. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3841 / 3850
页数:10
相关论文
共 41 条
[1]   A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure [J].
Antonis, Adriaan F. G. ;
Bruschke, Christianne J. M. ;
Rueda, Paloma ;
Maranga, Luis ;
Casal, J. Ignacio ;
Vela, Carmen ;
Hilgers, Luuk A. Th. ;
Belt, Peter B. G. M. ;
Weerdmeester, Klaas ;
Carrondo, Manuel J. T. ;
Langeveld, Jan P. M. .
VACCINE, 2006, 24 (26) :5481-5490
[2]   The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region [J].
Barnet, SW ;
Lu, S ;
Srivastava, I ;
Cherpelis, S ;
Gettie, A ;
Blanchard, J ;
Wang, S ;
Mboudjeka, I ;
Leung, L ;
Lian, Y ;
Fong, A ;
Buckner, C ;
Ly, A ;
Hilt, S ;
Ulmer, J ;
Wild, CT ;
Mascola, JR ;
Stamatatos, L .
JOURNAL OF VIROLOGY, 2001, 75 (12) :5526-5540
[3]   Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation [J].
Buonaguro, L ;
Visciano, ML ;
Tornesello, ML ;
Tagliamonte, M ;
Biryahwaho, B ;
Buonaguro, FM .
JOURNAL OF VIROLOGY, 2005, 79 (11) :7059-7067
[4]   Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A [J].
Buonaguro, L ;
Racioppi, L ;
Tornesello, ML ;
Arra, C ;
Visciano, ML ;
Biryahwaho, B ;
Sempala, SDK ;
Giraldo, G ;
Buonaguro, FM .
ANTIVIRAL RESEARCH, 2002, 54 (03) :189-201
[5]   Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 [J].
Bures, R ;
Gaitan, A ;
Zhu, TF ;
Graziosi, C ;
McGrath, KM ;
Tartaglia, J ;
Caudrelier, P ;
EL Habib, R ;
Klein, M ;
Lazzarin, A ;
Stablein, DM ;
Deers, M ;
Corey, L ;
Greenberg, ML ;
Schwartz, DH ;
Montefiori, DC .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) :2019-2035
[6]  
Burton DR, 2001, CURR TOP MICROBIOL, V260, P109
[7]   Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein [J].
Cao, J ;
Sullivan, N ;
Desjardin, E ;
Parolin, C ;
Robinson, J ;
Wyatt, R ;
Sodroski, J .
JOURNAL OF VIROLOGY, 1997, 71 (12) :9808-9812
[8]   CHARACTERIZATION OF A CD4-EXPRESSING MACAQUE CELL-LINE THAT CAN DETECT VIRUS AFTER A SINGLE REPLICATION CYCLE AND CAN BE INFECTED BY DIVERSE SIMIAN IMMUNODEFICIENCY VIRUS ISOLATES [J].
CHACKERIAN, B ;
HAIGWOOD, NL ;
OVERBAUGH, J .
VIROLOGY, 1995, 213 (02) :386-394
[9]   Recombinant human immunodeficiency Pr55(gag) virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies [J].
Deml, L ;
Schirmbeck, R ;
Reimann, J ;
Wolf, H ;
Wagner, R .
VIROLOGY, 1997, 235 (01) :26-39
[10]   Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1α, MIP-1β and RANTES β-chemokines [J].
Dolei, A ;
Biolchini, A ;
Serra, C ;
Curreli, S ;
Gomes, E ;
Dianzani, F .
AIDS, 1998, 12 (02) :183-190